RIPK3 and myocardial infarction: Arctiin significantly reduced myocardial I/R injury (myocardial infarction and creatine kinase release), while decreasing the levels of necroptosis-related proteins (RIPK1/p-RIPK1, RIPK3/p-RIPK3, and MLKL/p-MLKL) in the hearts of I/R-treated rats.